No benefit of an adjunctive phototherapy protocol in treatment of periodontitis: A split-mouth randomized controlled trial.

AIM: To assess the efficacy of a commercially available adjunctive phototherapy protocol ("Perio-1") in treatment of periodontitis. MATERIALS AND METHODS: In an examiner-blind, randomized, controlled, split-mouth, multicentre study, 60 periodontitis patients received root surface debridement (RSD) in sextants either alone (control sextants) or with the adjunctive phototherapy protocol (test sextants). Re-evaluation was performed at 6, 12 and 24 weeks. RESULTS: No statistically significant differences in mean (± standard deviation) clinical attachment level (CAL) change from baseline to week 24 were observed between test (-1.00 ± 1.16 mm) and control sextants (-0.87 ± 0.79 mm) at sites with probing pocket depths (PPDs) ≥5 mm ("deep sites") at baseline (p = .212). Comparisons between test and control sextants for all other parameters (CAL change at all sites, PPD change at deep sites/all sites, bleeding on probing, plaque scores), and for all change intervals, failed to identify any statistically significant differences. CONCLUSIONS: The phototherapy protocol did not provide any additional clinical benefits over those achieved by RSD alone. (German Clinical Trials Register DRKS00011229).

Melatonin promotes sleep in three species of diurnal nonhuman primates.

Nocturnal melatonin secretion is concurrent with consolidated sleep episodes in diurnal mammals and physiological melatonin levels can promote sleep onset in humans and in pigtail macaques. In order to further investigate the effects of melatonin treatment on sleep parameters in diurnal nonhuman primates, three macaque species have been studied: Macaca nemestrina, Macaca fascicularis, and Macaca mulatta. Sleep was assessed using continuous actigraphic recording of motor activity in animals maintained under 12:12-h light/dark cycle. Oral doses of melatonin (5-320 microg/kg) were administered 2 h before lights-off time, with 5- and 10-microg/kg doses resulting in physiological circulating melatonin levels (31-95 pg/ml). The effects of melatonin administration were similar in three species studied and included significantly earlier sleep onset time and longer sleep period time, with no difference in time of awakening, following administration of both physiological (5-10 microg/kg) and pharmacological (20-320 microg/kg) doses. While low melatonin doses (5-20 microg/kg) did not significantly affect nighttime sleep efficiency, higher pharmacological doses reduced sleep efficiency and increased sleep fragmentation at night, and reduced spontaneous daytime locomotor activity. Daily administration of a 5-microg/kg dose for 4 weeks or gradually escalating melatonin doses (5-320 microg/kg over a 3-week period) did not result in the development of tolerance or sensitization to the effect of melatonin on sleep initiation or sleep period. These data affirm that sleep-promoting effects of melatonin observed in humans are also typical for diurnal primates. They also suggest that physiological and pharmacological melatonin levels might produce different effects on sleep efficiency and that nonhuman primates can serve as adequate animal model for studying the mechanisms of melatonin's action on sleep and performance.